Home LiteratureArticle Details
PMID: 12205567 Published · ppublish English Journal Article

Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit.

Pediatric pulmonology ·Vol. 34 ·No. 4 ·2002-10-00 ·Pages 262-6

McCormick J, Tubman R

Abstract

We evaluated the incidence of readmission with respiratory syncytial virus (RSV) infection among the graduates of a regional Neonatal Intensive Care Unit (NICU), and characterized those who were rehospitalized. These data were used as a predictive tool to estimate the number of babies likely to suffer readmission with RSV for the year 2000 cohort. Using the published efficacies of palivizumab, the costs and benefits of protecting this cohort were assessed. Retrospective analysis of 2,507 NICU inpatient records from January 1, 1994-December 31, 1999 from the Royal Maternity Hospital, Belfast, were compared with data on positive RSV samples from 1,790 patients between January 1, 1995-December 31, 1999 from the Northern Ireland Regional Virus Laboratory. The analysis yielded 136 (7.6%) ex-NICU patients among the positive RSV samples over this 5-year period. Characteristic seasonal peaks of RSV infection with interseasonal variability were observed. Of those readmitted, 86.9% were hospitalized with RSV before their first birthday. A calculated readmission rate of 5.4% for all NICU graduates, and 6.4% for those <or=35 weeks, was found, leading to an expectation of 36 readmissions from the 668 NICU graduates in the year 2000 over the next 1-2 years, 20 of whom would be <or=35 weeks and 12 would be <or=32 weeks. A cost of pound 1.3 million would be required to protect the <or=35-week year 2000 cohort and prevent 11 readmissions. This equals pound 120,000 per admission prevented, or 28.2 patients treated to prevent 1 readmission. A readmission rate of 6.4% may differ from other studies, as it represents analysis of a greater number of RSV seasons. Using economic arguments alone, the cost of routine administration of Palivizumab to ex-NICU <or=35-week infants is prohibitive. A selective practice of immunizing those with chronic lung disease with a background of extreme prematurity over the November to March RSV season may be more cost-effective.

MeSH Terms
Antibodies, Monoclonal/economics,therapeutic use Antibodies, Monoclonal, Humanized Antiviral Agents/economics,therapeutic use Cohort Studies Cost-Benefit Analysis Female Humans Incidence Infant Infant, Newborn Intensive Care Units, Neonatal/economics Ireland/epidemiology Male Medical Audit Palivizumab Patient Readmission/economics,statistics & numerical data Probability Respiratory Syncytial Virus Infections/epidemiology,prevention & control Retrospective Studies Risk
Chemicals
Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antiviral Agents Palivizumab
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
McCormick Jonathan
Neonatal Intensive Care Unit, Royal Maternity Hospital, Belfast, Northern Ireland, UK. jdmccormick@btinternet.com
Tubman Richard
Article Info
Journal
Pediatric pulmonology
Abbr.
Pediatr Pulmonol
ISSN
8755-6863
Published
2002-10-00
Pages
262-6
Language
English
Region
United States
NLM ID
8510590
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com